What is regenerative medicine for a sore joint?

Cartilage regeneration needs proof that new tissue grew

Cartilage makes a smooth cap over the bone ends in a joint. Little blood reaches it, so worn cartilage doesn't readily replace itself. An X-ray or scan from before and after care can check for change. The person making the claim should show you that proof.

Joint regeneration can sound as though the whole joint became new. A joint also includes bone, tendons, and other tissue. Less swelling or stronger muscles may help you walk farther. That improvement doesn't mean every part of the joint changed.

Your daily comfort and an X-ray answer different questions.

If a treatment is said to rebuild tissue, ask what test showed it. You can value better sleep and easier movement without calling it new cartilage.

PRP is a shot made after your blood is spun

PRP stands for platelet-rich plasma, a shot prepared by taking some blood and separating it with a spinning machine. The liquid portion of blood is plasma. Platelets are tiny blood parts gathered in that liquid. Concentrated PRP has more of those platelets placed into the plasma before the shot.

Orthobiologics is the name for joint shots made from blood, marrow, fat, or other body tissue. Clinics don't always prepare it alike. Those differences may matter, so you'll want the clinic to name the exact shot.

After checking the joint, QC Kinetix may offer non-surgical regenerative treatments, including a shot that starts with drawn blood, for soreness that can come with arthritis.

The common question is whether PRP grows cartilage. Research doesn't support promising that it rebuilds a generally worn joint. It may still be discussed for less soreness or easier walking. Those results don't mean new cartilage grew.

Sources

1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

   Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

2. A Nature comment by Sipp, Robey and Turner arguing that loose use of 'mesenchymal stem cell' across an enormous range of unrelated cell preparations has produced a scientific and commercial mess, and calling for the terminology and the evidentiary standards to be tightened. Included because the objection to the word comes from inside stem cell science, not from its critics.

   Sipp D, et al. — Clear up this stem-cell mess.. Nature, 2018. DOI: 10.1038/d41586-018-06756-9.

3. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product.

   Tan AR, et al. — Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.16-0271.

4. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

5. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.